
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
Photodynamic therapy with verteporfin is the most promising of the FDA-approved therapies for exudative CNV.




